In this article, we aimed to identify the efficacy and safety of SGLT2 inhibitors in adults with overweight or obesity but not diabetes in randomized controlled studies (RCTs). This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.